§ 13F · FUND PROFILE
Aisling Capital Management LP.
Institutional filer · behavioral pattern: Other. Summary pending.
AUM · $359.7T (13F)Positions · 13Turnover · — · Q4Filed · Feb 10, 2026
CONCENTRATION
—
Top 10 holdings
NEW BUYS
0
+$2.5T deployed
EXITS
0
No exits
SECTOR SHIFT
—
No prior quarter data
3YR HIT RATE
—
Top-5 overlap
§ 01 · TOP HOLDINGS
The book · Q4 2025
FILED FEB 10, 2026
| # | Ticker | Name | Shares | $ value | % port | Δ Q4 |
|---|---|---|---|---|---|---|
| 1 | BBIO | BridgeBio Pharma Inc. (BBIO) | 5.09M | $389.3T | 81.3% | −16% |
| 2 | SNDX | Syndax Pharmaceuticals, Inc. (SNDX) | 1.32M | $27.7T | 5.8% | ±0% |
| 3 | GLUE | Monte Rosa Therapeutics Inc (GLUE) | 1.47M | $23.1T | 4.8% | ±0% |
| 4 | BCAX | Bicara Therapeutics Inc. (BCAX) | 569K | $9.6T | 2.0% | ±0% |
| 5 | CMPS | Compass Pathways Plc (CMPS) | 1.20M | $8.3T | 1.7% | ±0% |
| 6 | BBOT | BridgeBio Oncology Therapeutics (BBOT) | 565K | $7.1T | 1.5% | ±0% |
| 7 | CALC | CalciMedica, Inc. (CALC) | 521K | $3.4T | 0.7% | ±0% |
| 8 | SRRK | Scholar Rock Holding Corporation (SRRK) | 77K | $3.4T | 0.7% | ±0% |
| 9 | BMEA | Biomea Fusion Inc (BMEA) | 2.05M | $2.5T | 0.5% | ±0% |
| 10 | URGN | Urogen Pharma Ltd. (URGN) | 108K | $2.5T | 0.5% | NEW |
§ 02 · SECTOR ALLOCATION
Where the money is
Sector data pending
§ 03 · THE AISLING SIGNAL
AC read
Aisling Capital Management LP is a Other fund managing $359671.7 trillion in assets. The fund runs a focused portfolio of just 13 positions.
Read the full dossier →§ 04 · FILING HISTORY
Q-by-Q deltas
1 FILINGS
Q4 2025
Steady book
+0 buys · −0 exits · 0 changed
Q3 2025
Steady book
+0 buys · −0 exits · 0 changed
Q2 2025
Steady book
+0 buys · −0 exits · 0 changed
Q1 2025
Steady book
+0 buys · −0 exits · 0 changed